Archive - RAS Dialogue
- Genetic Ablation of KRAS in Pancreas Cancer: When an Essential Oncogene Isn’t
Of all cancers, pancreatic cancers are most dependent on mutant KRAS. However, many pancreatic cancer cell lines survive loss of their mutant KRAS genes. The adaptations these lines make provide opportunities for treating these deadly cancers.
- RAS and MYC: Co-conspirators in Cancer
The transcription factor MYC is an important downstream target of mutated RAS genes in human cancers. Inhibiting post-translational modifications of MYC to decrease its transcriptional activity is a new strategy for treating RAS-driven cancers.